Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Breast 3Gynecologic 2Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Alendronate × Gynecologic × Clear all
NCT07245381 2025-11-24

Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation

Sheba Medical Center

Phase 1/2 Not yet recruiting
65 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00593580 2011-06-29

FOSAVANCE

British Columbia Cancer Agency

Phase 2 Completed
60 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡